A mother from the UK has become the world’s first recipient of a novel vaccine aimed at enhancing lung cancer treatment. Chris Jones, 68, received the vaccine, utilizing cells from her own tumor to develop synthetic DNA, in a pioneering clinical trial at the Clatterbridge Cancer Centre in Liverpool.
The experimental treatment marks a significant advancement in immunotherapy according to one of the consultants leading the trial. Chris, a resident of Hoylake, Merseyside, is battling advanced non-small cell lung cancer, a prevalent form of lung cancer. While her ongoing immunotherapy has shown some efficacy, it has not delivered optimal results.
Dr. Carles Escriu, a Medical Oncology Consultant, highlighted that a considerable number of patients experience a temporary response to immunotherapy before the cancer develops resistance. The objective of the new vaccine is to bolster the immune system to achieve a prolonged therapeutic response.
Chris willingly joined the early-stage clinical trial in hopes of extending her life and aiding future patients. Recalling the loss of her daughter to cancer, she emphasized the importance of such trials in advancing treatment options.
The personalized vaccine, tailored specifically for Chris, was engineered using synthetic DNA derived from her tumor biopsy. Dubbed “doggybone” due to its distinct structure, this DNA offers a faster and more cost-effective production method, making personalized vaccines more feasible for healthcare systems like the NHS.
A collaborative effort involving the University of Liverpool, the Clatterbridge Cancer Centre, NHS Blood and Transplant, and specialist genetic and immunotherapy companies culminated in the development of this groundbreaking vaccine. With only ten participants in the initial trial set to receive seven doses over 24 weeks, the lead professors anticipate improved care for a significant portion of advanced lung cancer patients.
Professors Ottensmeier and Savelyeva aim to enhance the immune system’s ability to identify and combat tumors that have evaded detection. Their research endeavors to reshape conventional cancer vaccine strategies in the treatment of advanced lung cancer, offering hope for better patient outcomes.
